The effectiveness of adding a cognitive behavioural therapy aimed at changing lifestyle to an optimal diabetes care system

Submission date	Recruitment status No longer recruiting	Prospectively registered		
12/09/2005		[X] Protocol		
Registration date	Overall study status	Statistical analysis plan		
12/09/2005 Last Edited	Completed Condition category	Results		
		Individual participant data		
23/09/2021	Nutritional, Metabolic, Endocrine	Record updated in last year		

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Ms Corina van den Hurk

Contact details

Zernikestraat 29 Eindhoven Netherlands 5612 HZ

Additional identifiers

Protocol serial number

NL68 (NTR92)

Study information

Scientific Title

The effectiveness of adding a cognitive behavioural therapy aimed at changing lifestyle to an optimal diabetes care system

Study objectives

A cognitive behaviour intervention is more effective in achieving behavioural changes and therefore changes in lifestyle and cardiovascular risk profile than usual care in patients with type two diabetes.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved by the Medical Ethical Committee of the VU University Medical Center Amsterdam.

Study design

Randomised, active controlled, factorial, single blinded trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Diabetes Mellitus type II (DM type II)

Interventions

Intervention group:

A Cognitive Behavioural Therapy (CBT) which consist of a Motivational Interviewing phase and a Problem Solving Treatment phase. The CBT will be performed by dieticians and diabetes nurses and includes six individual sessions of 30 minutes. This sessions will be performed within a period of 16 weeks.

Usual care group:

Usual care by general practitioner/practice nurse and an annual check-up Diabetes Research Centre as is usual in the optimal care system where the study will be performed.

Both groups will be measured at baseline, at six and at 12 months. Measurements include: demographic patient characteristics, patients' history, diabetes care, clinical patients' characteristics (weight, height, waist circumference, foot inspection, blood pressure, fasting plasma glucose, HbA1c, total cholesterol, High Density Lipoprotein [HDL]-cholesterol) and questionnaires.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

1. Differences between intervention and usual care groups in changes in diet, physical activity and smoking behaviour according to the ASE-model, a health behaviour model that assumes that behaviour is determined by attitude (A), social influences (S) and self-efficacy (E)

2. Changes in cardiovascular risk score based on the Oxford Risk Engine (algorithm that includes: age at diagnosis, duration of diabetes, sex, ethnicity, smoking status, systolic blood pressure, HbA1c, total cholesterol, HDL-cholesterol). A risk reduction of 5% is clinical relevant.

Key secondary outcome(s))

- 1. Quality of life
- 2. Patient satisfaction
- 3. Changes in medication use, adherence to prescribed medication
- 4. Proportion of patients reaching treatment targets according to the guidelines of the Dutch College of General practitioners
- 5. Adherence to the 3-monthly visit to the general practitioner

Completion date

31/12/2006

Eligibility

Key inclusion criteria

- 1. Patients with type two diabetes from general practices with the support of a practice nurse
- 2. Age 40 to 70 years
- 3. Written informed consent
- 4. Capable to fill in questionnaires
- 5. Understanding of Dutch language
- 6. HbA1c more than 7.0 % and/or Body Mass Index (BMI) more than 27.0 kg/m^2 and/or smoking

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Not Specified

Key exclusion criteria

- 1. Unstable endocrine disorders, with the exception of diabetes
- 2. Malignant disease
- 3. Treatment with corticosteroids
- 4. Serious mental impairment, i.e. preventing to understand the study protocol

Date of first enrolment

01/09/2005

Date of final enrolment

31/12/2006

Locations

Countries of recruitment

Netherlands

Study participating centre Zernikestraat 29 Eindhoven Netherlands 5612 HZ

Sponsor information

Organisation

VU University Medical Centre (The Netherlands)

ROR

https://ror.org/00q6h8f30

Funder(s)

Funder type

Research council

Funder Name

EMGO Institute (The Netherlands) - internal funding

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	Study protocol	08/05/2007		Yes	No